Compare · QSI vs TXG
QSI vs TXG
Side-by-side comparison of Quantum-Si Incorporated (QSI) and 10x Genomics Inc. (TXG): market cap, price performance, sector, and recent activity on the wire.
Summary
- QSI operates in Industrials, while TXG operates in Health Care - the two are in different parts of the market.
- TXG is the larger of the two at $7.41B, about 33.4x QSI ($221.9M).
- TXG has been more active in the news (11 items in the past 4 weeks vs 6 for QSI).
- TXG has more recent analyst coverage (25 ratings vs 4 for QSI).
- Company
- Quantum-Si Incorporated
- 10x Genomics Inc.
- Price
- -
- -
- Market cap
- $221.9M
- $7.41B
- 1M return
- -
- -19.84%
- 1Y return
- -
- +267.92%
- Industry
- Industrial Machinery/Components
- Biotechnology: Laboratory Analytical Instruments
- Exchange
- NASDAQ
- NASDAQ
- IPO
- 2020
- 2019
- News (4w)
- 6
- 11
- Recent ratings
- 4
- 25
Quantum-Si Incorporated
Quantum-Si incorporated operates first next-generation protein sequencing and genomics platform for healthcare industries. It offers a single molecule detection solution to decode the molecules of life, including sample preparation, single molecule, massively parallel, and protein identification. The company's technology has the applications in proteomics, single cell, transcriptomics, genomics, metabolomics, and drug testing and screening fields. The company is based in Guilford, Connecticut. Quantum-Si incorporated is a subsidiary of 4Catalyzer Corporation.
10x Genomics Inc.
10x Genomics, Inc., a life science technology company, develops and sells instruments, consumables, and software for analyzing biological systems in North America, Europe, the Middle East, Africa, China, and the Asia Pacific. The company provides chromium and chromium connect instruments, microfluidic chips, slides, reagents, and other consumables products. Its single cell solutions runs on its chromium instruments, which include single cell gene expression for measuring gene activity on a cell-by-cell basis; single cell immune profiling for measuring the activity of immune cells and their targets; single cell ATAC for measuring epigenetics comprising the physical organization of DNA; and single cell multiome ATAC + gene expression for measuring the genetic activity and epigenetic programming in the same cells across tens of thousands of cells in a single experiment. The company also provides visium spatial gene expression solution for measuring spatial gene expression patterns across a single tissue sample or gene expression and protein co-detection when combined with immunofluorescence. It serves various academic, government, biopharmaceutical, biotechnology, and other institutions. The company was formerly known as 10X Technologies, Inc. and changed its name to 10x Genomics, Inc. in November 2014. 10x Genomics, Inc. was incorporated in 2012 and is headquartered in Pleasanton, California.
Latest QSI
- Quantum-Si Incorporated filed SEC Form 8-K: Regulation FD Disclosure, Financial Statements and Exhibits
- Quantum-Si Achieves Historic Milestone in Protein Sequencing with Single-Molecule Detection of All 20 Amino Acids on Proteus™
- Quantum-Si Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
- SEC Form 10-Q filed by Quantum-Si Incorporated
- Quantum-Si Incorporated filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits
- Quantum-Si Reports Third Quarter 2026 Financial Results and Provides Business Update
- Quantum-Si to Provide a Business Update and Report Third Quarter 2026 Financial Results on November 5, 2026
- SEC Form 8-K filed by Quantum-Si Incorporated
- Quantum-Si Regains Compliance with Nasdaq Minimum Bid Price Requirement
- SEC Form 8-K filed by Quantum-Si Incorporated
Latest TXG
- 10x Genomics Expands Global Research in Blood-Based Diagnostics for Autoimmune Disease with Two New Collaborations
- Amendment: SEC Form SCHEDULE 13G/A filed by 10x Genomics Inc.
- Chief Executive Officer Saxonov Serge sold $1,949,900 worth of shares (31,000 units at $62.90), decreasing direct ownership by 3% to 1,019,249 units (SEC Form 4)
- Shanghai Precision Diagnostics and Fudan University Shanghai Cancer Center Launch Breast Cancer Biomarker Study Using 10x Genomics' Xenium Platform
- SEC Form 3 filed by new insider Satpathy Ansuman
- New insider Gilliam Joseph E claimed ownership of 31 shares (SEC Form 3)
- 10x Genomics Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits
- 10x Genomics Reports Third Quarter 2026 Financial Results
- 10x Genomics Inc. filed SEC Form 8-K: Leadership Update
- 10x Genomics Launches Sentira Single Cell, A New Agentic AI Experience for Chromium Analysis